Somatostatin versus secretin in the treatment of actively bleeding gastric erosions

Zsolt Tulassay, András Bodnár, Ivan Farkas, János Papp, Ramesh Gupta

Research output: Article

4 Citations (Scopus)


In a double-blind, prospective, randomized trial, 63 patients with actively bleeding gastric erosions were treated with somatostatin (31 patients) or secretin (32 patients). Both drugs were administered by intravenous infusions for 48 or 72 h. The active bleeding and the effect of the therapy was endoscopically established. Somatostatin had a significantly (p < 0.05) better effect on the control of bleeding (29 vs. 23 patients), transfusion requirements (5.8 vs. 7.4 units, p < 0.01) and on the need of surgery (1 vs. 6 patients, p < 0.01). The mortality and the rebleeding rate did not differ between the two groups. The results show that somatostatin is more effective than secretin in the control of active bleeding form gastric erosions.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
Issue number4
Publication statusPublished - jan. 1 1992

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Somatostatin versus secretin in the treatment of actively bleeding gastric erosions'. Together they form a unique fingerprint.

  • Cite this